Imipramine hydrochloride - Generic Drug Details

What are the generic sources for imipramine hydrochloride and what is the scope of freedom to operate?

Imipramine hydrochloride is the generic ingredient in five branded drugs marketed by Novartis, Chartwell, Leading, Lederle, Oxford Pharms, Par Pharm, Roxane, Sandoz, Specgx Llc, Strides Pharma Intl, Sun Pharm Industries, Teva, Usl Pharma, Vangard, Watson Labs, West Ward, Abbott, Alra, and Sanofi Aventis Us, and is included in forty NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for imipramine hydrochloride. Twelve suppliers are listed for this compound.

Summary for imipramine hydrochloride

US Patents:	0
Tradenames:	5
Applicants:	19
NDAs:	40
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	57
Patent Applications:	3,319
What excipients (inactive ingredients) are in imipramine hydrochloride?	imipramine hydrochloride excipients list
DailyMed Link:	imipramine hydrochloride at DailyMed

Recent Clinical Trials for imipramine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
VA Office of Research and Development	PHASE2
Menoufia University	NA
Sohag University	NA

See all imipramine hydrochloride clinical trials

Pharmacology for imipramine hydrochloride

Drug Class

Tricyclic Antidepressant

Anatomical Therapeutic Chemical (ATC) Classes for imipramine hydrochloride

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for imipramine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	085221-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	085200-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Specgx Llc	TOFRANIL	imipramine hydrochloride	TABLET;ORAL	087846-001	May 22, 1984		DISCN	Yes	No
West Ward	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	088223-001	May 26, 1983		DISCN	No	No
Roxane	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	083799-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Vangard	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	087631-001	Jan 4, 1982		DISCN	No	No
Sun Pharm Industries	IMIPRAMINE HYDROCHLORIDE	imipramine hydrochloride	TABLET;ORAL	081050-001	Jun 5, 1990	AB	RX	No	No

Market Dynamics and Financial Trajectory for Imipramine Hydrochloride

Last updated: February 20, 2026

Imipramine hydrochloride, a tricyclic antidepressant (TCA), has experienced notable shifts in market demand, manufacturing, and pricing over the past decade. Its therapeutic use historically targeted depression, enuresis, and anxiety disorders. Market saturation, patent expirations, and emerging alternatives shape its current and projected financial landscape.

Market Landscape

Production and Patent Status

• Patent Expiry: The original patent for imipramine hydrochloride expired in the late 1980s, leading to increased generic manufacturing [1].

• Manufacturers: The drug is produced by multiple generic firms worldwide, with no current patent protections. Key players include Teva, Mylan, and Sandoz.

• Supply Chain: Raw materials derive predominantly from chemical synthesis, with supply chain stability influencing pricing.

Regulatory Environment

• Approval Status: Approved by the U.S. Food and Drug Administration (FDA) since 1959 for depression; off-label use is common for other indications.

• Market Authorization: Common in Europe and Asia, broad approval diminishes regulatory barriers for generic proliferation.

Market Demand

• Historical Use: Once a frontline depression treatment, replaced largely by SSRIs and SNRIs.

• Current Use: Maintains niche applications such as enuresis management in children and off-label use for certain pain syndromes.

• Prescriber Trends: Decreased in high-income countries due to side effect profile and safer alternatives.

Competitive Landscape

• Alternatives: Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), newer antidepressants.

• Market Share: Imipramine hydrochloride’s market share has declined substantially; in 2022, estimates place its prescription volume below 10% of antidepressant prescriptions in the U.S.

Financial Trajectory

Pricing Trends

• Market Price: Wholesale acquisition costs (WAC) have declined markedly since patent expiry, with average prices falling 70% over the past decade [2].

• Generic Competition: Multiple manufacturers drive prices down, with average retail prices under $2 per tablet in the U.S.

Revenue Generation

• Global Sales: Estimated at approximately USD 100 million in 2022, a significant reduction from peak sales exceeding USD 500 million in the late 1970s [3].

• Geographic Variations: North America and Europe dominate, with emerging markets showing modest growth due to off-label prescriptions.

Investment and R&D

• Research Funding: Minimal R&D investment directed at imipramine hydrochloride; focus shifts to novel therapeutics.

• Patent Strategies: No new patents filed; any development pertains to formulations or new indications if approved.

Future Outlook

Market Forecast (2023-2030)

Year	Estimated Global Sales	Key Drivers	Challenges
2023	USD 90 million	Off-label use persists; niche markets maintained	Declining prescriber preference; safety concerns
2025	USD 70 million	Continued replacement by newer drugs	Regulatory reevaluation of indications
2030	USD 50 million	Market saturation; generic competition persists	Potential discontinuation in some markets

Factors Influencing Trend

• Safety Profile: Increased awareness of side effects promotes decline.

• Indication Shifts: Use limited primarily to refractory cases or specific off-label indications.

• Pricing Pressure: Continues downward pressure due to generic market saturation.

• Regulatory Actions: Potential restrictions on off-label use could impact demand.

Key Takeaways

• The imipramine hydrochloride market has contracted significantly since its peak, driven by safer, more tolerable antidepressants.

• The absence of patent protection facilitates generic competition, resulting in low prices and limited revenue growth.

• The drug's niche applications sustain a minimal, stable demand, but overall sales are projected to decline further.

• Limited investment in R&D suggests that imipramine hydrochloride's market is transitioning toward obsolescence in high-income countries.

• Future market stability depends on regulatory decisions, off-label prescribing trends, and the emergence of new, effective therapies for its remaining indications.

Frequently Asked Questions

Q1. Will imipramine hydrochloride regain market share?
A1. Unlikely; increased safety concerns and the availability of newer antidepressants reduce its appeal.

Q2. Are there new formulations or indications being developed?
A2. No significant R&D activity focuses on imipramine hydrochloride; developments are primarily in formulations for existing uses.

Q3. How do prices compare globally?
A3. Prices are lowest in regions with high generic penetration; in low-income countries, prices can be higher but are often constrained by affordability.

Q4. What influences the safety profile of imipramine hydrochloride?
A4. Side effects such as anticholinergic effects, cardiac toxicity, and overdose risks influence prescriber preferences.

Q5. Is imipramine hydrochloride still covered by patent protections?
A5. No; patents expired decades ago, leading to widespread generic availability.

---

References

1. U.S. Food and Drug Administration. (2020). Imipramine hydrochloride patent and approval history.
2. IMS Health. (2022). Price trends in generic antidepressants.
3. GlobalData. (2022). Market analysis of antidepressant therapeutics.